| 1 |
34791695 | 3D-QSAR, molecular docking, molecular dynamics, and ADME/T analysis of marketed and newly designed flavonoids as inhibitors of Bcl-2 family proteins for targeting U-87 glioblastoma. | 2022 Feb |
1 |
| 2 |
35013156 | Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy. | 2022 Jan 10 |
1 |
| 3 |
35172148 | BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer. | 2022 Feb 15 |
1 |
| 4 |
35187492 | ATP Synthase K+- and H+-fluxes Drive ATP Synthesis and Enable Mitochondrial K+-"Uniporter" Function: II. Ion and ATP Synthase Flux Regulation. | 2022 |
1 |
| 5 |
35332309 | BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells. | 2022 Mar 24 |
1 |
| 6 |
35473984 | Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. | 2022 Apr 26 |
1 |
| 7 |
35583342 | Single-Molecule Sensing of an Anticancer Therapeutic Protein-Protein Interaction Using the Chemically Modified OmpG Nanopore. | 2022 May 31 |
3 |
| 8 |
32079453 | Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets. | 2021 Jan 2 |
1 |
| 9 |
33068701 | Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers. | 2021 Jan 28 |
1 |
| 10 |
33241675 | Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis | 2021 Dec 1 |
1 |
| 11 |
33495554 | Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL. | 2021 May |
1 |
| 12 |
34257274 | Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy. | 2021 Jul 13 |
1 |
| 13 |
34315868 | Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer. | 2021 Jul 27 |
1 |
| 14 |
34478517 | Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. | 2021 Oct 26 |
3 |
| 15 |
34493661 | Lipids modulate the BH3-independent membrane targeting and activation of BAX and Bcl-xL. | 2021 Sep 14 |
1 |
| 16 |
34781947 | Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas. | 2021 Nov 16 |
2 |
| 17 |
31388792 | A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. | 2020 Jun |
1 |
| 18 |
32203216 | A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. | 2020 May |
4 |
| 19 |
32411238 | Cell Survival Is Regulated via SOX9/BCL2L1 Axis in HCT-116 Colorectal Cancer Cell Line. | 2020 |
1 |
| 20 |
32457483 | BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer. | 2020 Nov |
2 |
| 21 |
32484436 | MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. | 2020 Jun 2 |
1 |
| 22 |
32569380 | Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. | 2020 Jun 23 |
1 |
| 23 |
32715755 | Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment. | 2020 Oct |
1 |
| 24 |
32801295 | Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance. | 2020 Aug 15 |
1 |
| 25 |
33017468 | BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma. | 2020 Oct 13 |
1 |
| 26 |
33023187 | Profiling Anti-Apoptotic BCL-xL Protein Expression in Glioblastoma Tumorspheres. | 2020 Oct 2 |
1 |
| 27 |
33146015 | Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-XL: Role of Non-Hot Spot Residues. | 2020 Nov 17 |
1 |
| 28 |
33198338 | BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic. | 2020 Nov 12 |
1 |
| 29 |
29924730 | Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations. | 2019 Jan 28 |
2 |
| 30 |
30185825 | BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL. | 2019 Jun |
1 |
| 31 |
30389373 | Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis. | 2019 Feb |
1 |
| 32 |
30467206 | Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. | 2019 May |
1 |
| 33 |
30470795 | Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. | 2019 Jul |
1 |
| 34 |
30538285 | By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737. | 2019 Sep |
1 |
| 35 |
30860026 | Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2. | 2019 Mar 12 |
2 |
| 36 |
31228231 | Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. | 2019 Aug |
1 |
| 37 |
31324803 | Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction. | 2019 Jul 19 |
5 |
| 38 |
31341643 | DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis. | 2019 |
2 |
| 39 |
31439373 | NMR characterization of the interaction between Bcl-xL and the BH3-like motif of hepatitis B virus X protein. | 2019 Oct 20 |
1 |
| 40 |
31638265 | BH3 profiling discriminates the anti‑apoptotic status of 5‑fluorouracil‑resistant colon cancer cells. | 2019 Dec |
1 |
| 41 |
31801941 | Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML. | 2019 Dec 4 |
1 |
| 42 |
28947136 | BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis. | 2018 Jan 1 |
2 |
| 43 |
29233828 | E2F1 interacts with BCL-xL and regulates its subcellular localization dynamics to trigger cell death. | 2018 Feb |
1 |
| 44 |
29459767 | Mcl-1 and Bcl-xL sequestration of Bak confers differential resistance to BH3-only proteins. | 2018 Mar |
1 |
| 45 |
29580266 | Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines. | 2018 Mar 27 |
1 |
| 46 |
29682179 | Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. | 2018 Mar 30 |
1 |
| 47 |
29928488 | Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. | 2018 Jun 1 |
1 |
| 48 |
30021909 | Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. | 2018 Nov 1 |
1 |
| 49 |
30185782 | BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. | 2018 Sep 5 |
1 |
| 50 |
30254092 | Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer. | 2018 Dec |
2 |